Patents by Inventor Marco HERLING

Marco HERLING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tinostamustine for use in the treatment of T-cell prolymphocytic leukaemia
    Patent number: 11918558
    Abstract: T-PLL Therapy There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.
    Type: Grant
    Filed: April 27, 2022
    Date of Patent: March 5, 2024
    Assignee: Purdue Pharma L.P.
    Inventors: Thomas Jorg Mehrling, Marco Herling
  • TINOSTAMUSTINE FOR USE IN THE TREATMENT OF T-CELL PROLYMPHOCYTIC LEUKAEMIA
    Publication number: 20220401417
    Abstract: T-PLL Therapy There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.
    Type: Application
    Filed: April 27, 2022
    Publication date: December 22, 2022
    Inventors: Thomas Jorg Mehrling, Marco Herling
  • Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia
    Patent number: 11318117
    Abstract: T-PLL Therapy There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: May 3, 2022
    Assignee: Purdue Pharma L.P.
    Inventors: Thomas Jorg Mehrling, Marco Herling
  • TINOSTAMUSTINE FOR USE IN THE TREATMENT OF T-CELL PROLYMPHOCYTIC LEUKAEMIA
    Publication number: 20200113871
    Abstract: T-PLL Therapy There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of T-cell prolymphocytic leukemia (T-PLL) in a patient in need thereof.
    Type: Application
    Filed: June 13, 2018
    Publication date: April 16, 2020
    Applicant: PURDUE PHARMA L.P.
    Inventors: Thomas Jorg MEHRLING, Marco HERLING